These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 34981829)

  • 21. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
    Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
    Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
    Crowley JJ; Langley RG; Gordon KB; Pinter A; Ferris LK; Rubant S; Photowala H; Xue Z; Wu T; Zhan T; Beeck S; Shah M; Warren RB
    Dermatol Ther (Heidelb); 2022 Feb; 12(2):561-575. PubMed ID: 35050485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
    Papp KA; Weinberg MA; Morris A; Reich K
    Lancet; 2021 Apr; 397(10284):1564-1575. PubMed ID: 33894834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
    Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study.
    Zheng M; Chen X; Wang F; Chen J; Jackson K; Yang F; Payne C; Li H; Wang Y; Xiao Z; Zheng J
    Adv Ther; 2023 Sep; 40(9):3804-3816. PubMed ID: 37356077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.
    Bodemer C; Kaszuba A; Kingo K; Tsianakas A; Morita A; Rivas E; Papanastasiou P; Keefe D; Patekar M; Charef P; Zhang L; Cafoncelli S; Papavassilis C
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):938-947. PubMed ID: 33068444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
    Papp KA; Gooderham M; Lynde C; Brassard D; Al-Mohammedi F; Prajapati VH; Delorme I; Albrecht L; Haydey R; Alam MS; Beecker J; Siddha S; Maguin M; Farag MS; Vieira A; Rihakova L; Langley RG
    Arch Dermatol Res; 2024 Jun; 316(7):362. PubMed ID: 38850346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
    van de Kerkhof P; Guenther L; Gottlieb AB; Sebastian M; Wu JJ; Foley P; Morita A; Goldblum O; Zhang L; Erickson J; Ball S; Rich P
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):477-482. PubMed ID: 27910156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE).
    Warren RB; Barker JNWB; Finlay AY; Burden AD; Kirby B; Armendariz Y; Williams R; Hatchard C; Khare S; Griffiths CEM
    Br J Dermatol; 2020 Jul; 183(1):60-70. PubMed ID: 31628677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
    Gottlieb AB; Merola JF; Reich K; Behrens F; Nash P; Griffiths CEM; Bao W; Pellet P; Pricop L; McInnes IB
    Br J Dermatol; 2021 Dec; 185(6):1124-1134. PubMed ID: 33913511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study.
    Valenzuela F; de la Cruz Fernandez C; Galimberti RL; Gürbüz S; McKean-Matthews M; Goncalves L; Romiti R
    Actas Dermosifiliogr; 2017; 108(6):550-563. PubMed ID: 28342534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial.
    Lacour JP; Paul C; Jazayeri S; Papanastasiou P; Xu C; Nyirady J; Fox T; Papavassilis C
    J Eur Acad Dermatol Venereol; 2017 May; 31(5):847-856. PubMed ID: 28111801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis.
    Cai L; Zhang JZ; Yao X; Gu J; Liu QZ; Zheng M; Zhang SF; Xu JH; Li CX; Cheng H; Guo Q; Pan WL; Li SQ; Li RY; Guo ZP; Song ZQ; Li SS; Dong XQ; Wang L; Fu R; Regnault P; Charef P; Mazur R; Patekar M
    Chin Med J (Engl); 2020 Nov; 133(22):2665-2673. PubMed ID: 33060370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial.
    Puig L; Bakulev AL; Kokhan MM; Samtsov AV; Khairutdinov VR; Morozova MA; Zolkin NA; Kuryshev IV; Petrov AN; Artemeva AV; Zinkina-Orikhan AV
    Dermatol Ther (Heidelb); 2021 Aug; 11(4):1319-1332. PubMed ID: 34060012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
    Papp KA; Leonardi CL; Blauvelt A; Reich K; Korman NJ; Ohtsuki M; Paul C; Ball S; Cameron GS; Erickson J; Zhang L; Mallbris L; Griffiths CEM
    Br J Dermatol; 2018 Mar; 178(3):674-681. PubMed ID: 28991370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.